Breathe Well Live Well
|
GSK's First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar Potential
Seeking Alpha Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can … |
View full post on asthma – Google News
|
Teva's asthma candidates successful in three late-stage studies; regulatory …
Seeking Alpha Top-line results from three Phase 3 clinical trials assessing Teva Pharmaceutical Industries' (TEVA +0.4%) fluticasone propionate/salmeterol, a combination inhaled corticosteroid and long-acting beta agonist delivered via a multidose dry powder inhaler … |
View full post on asthma – Google News
Nasdaq |
FDA clears Teva asthma med (TEVA)
Seeking Alpha (registration) The FDA approves Teva Pharmaceutical Industries' (NYSE:TEVA) ProAir RespiClick (albuterol sulfate) inhalation powder for the treatment or prevention of bronchospasm in patients at least 12 years old with reversible obstructive airway disease and for … Teva Announces FDA Approval of ProAir® RespiClick Teva Announces FDA Approval of ProAir(R) RespiClick |
View full post on asthma – Google News
|
Investors appear to wake up to potential of BioTime's Asthma iPhone app (BTX)
Seeking Alpha (registration) Thinly-traded small cap BioTime (BTX +16.1%) jumps on a 4x surge in volume in (what appears to be) belated response to the March 9 announcement by Mount Sinai's Icahn School of Medicine that it is launching a large-scale research study of asthma using … |
View full post on asthma – Google News
|
A Quick Review Of The Asthma Market
Seeking Alpha (registration) Asthma remains a major health concern, with the WHO estimating the number of people suffering from asthma at 235 million. In the U.S., the CDC reports asthma prevalence at 9% in children and 8% in adults (CDC 2012). Even social media trends identify a … |
View full post on asthma – Google News
|
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha (registration) The three highest doses of dupilumab in combination with standard-of-care therapy met the primary endpoint of a statistically significant improvement from baseline in forced expiratory volume over one second (FEV1) at week 12 in patients with high … |
View full post on asthma – Google News
|
Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In …
Seeking Alpha After the close of the markets on Wednesday, October 9, 2013, Dynavax (DVAX) announced it will begin dosing patients in the first human trial in its asthma program. The trial, which is being conducted under a collaborative agreement with AstraZeneca … |
View full post on asthma – Google News
|
Regeneron's New Asthma Drug And Its Fierce Competitors
Seeking Alpha There are a large variety of asthma drugs on the market, but the most they can do is alleviate symptoms. They do little about the substance of the disease. Dupilumab, an injectable medication being developed by Regeneron Pharmaceuticals (REGN) and … |
View full post on asthma – Google News
|
Clearing The Air On The Sanofi-Regeneron Asthma Drug Trial
Seeking Alpha Results announced this week of a clinical trial testing the drug dupilumab, made by the biotechnology company Regeneron Pharmaceuticals (REGN) and global pharmaceutical company Sanofi (SNY) gave hope to asthma sufferers and got the attention of … |
View full post on asthma – Google News
|
Dynavax Advances Agonist For Asthma Into The Clinic
Seeking Alpha Dynavax Technologies Corporation (DVAX) announced this morning it will advance its proprietary second-generation TLR-9 agonist for asthma into Phase 1 clinical studies. The work will be performed under the terms of a collaboration with AstraZeneca … Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma |
View full post on asthma – Google News